Anzeige
Mehr »
Dienstag, 15.09.2026 - Börsentäglich über 12.000 News
80,4 g/t Gold und 131 g/t Silber: Was, wenn die alten Minen erst der Anfang waren?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
NB

WKN: A3DNSU | ISIN: CA67059R1091 | Ticker-Symbol: J90
Tradegate
15.09.26 | 08:18
0,413 Euro
+6,72 % +0,026
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NUREXONE BIOLOGIC INC Chart 1 Jahr
5-Tage-Chart
NUREXONE BIOLOGIC INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3820,41214:47
0,3860,41314:43

Aktuelle News zur NUREXONE BIOLOGIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
NUREXONE BIOLOGIC Aktie jetzt für 0€ handeln
11:30KAUFWELLE bei Nurexone Biologic: +2,56% und die Chancen steigen weiter!
02:18Nurexone Biologic Inc: Nurexone Biologic signs MOU with NanoPass Technologies15
MoNurExone Biologic Inc: NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications119TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based...
► Artikel lesen
MiNurExone Biologic: Was der NASDAQ-Plan auslösen kann57
02.09.NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing43
31.08.NurExone Biologic reports Q2 results27
31.08.NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results574TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...
► Artikel lesen
21.08.Nurexone Biologic Inc: Nurexone Biologic schedules AGSM for Sept. 1544
21.08.NurExone Biologic Inc: NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy554Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic...
► Artikel lesen
20.08.NurExone Biologic Inc: NurExone Announces Closing of C$1,066,078 Private Placement346TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based...
► Artikel lesen
14.08.Nurexone Biologic Inc: Nurexone releases preclinical data supporting ExoPTEN54
14.08.NurExone Biologic Inc: NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model918TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...
► Artikel lesen
13.08.Nurexone Biologic Inc: Nurexone Biologic signs MOU with Made Scientific29
12.08.NurExone Biologic Inc: NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership258TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...
► Artikel lesen
31.07.Nurexone Biologic Inc: Nurexone to apply Novasign platform for production29
28.07.NurExone Biologic Inc: Corporate Updates - NurExone appoints Mr. David Stolick to the Board of Directors337TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
01.07.Nurexone Biologic Inc: Nurexone Biologic closes $627,795 private placement69
30.06.NurExone Biologic Inc: NurExone Announces Closing of Non-Brokered Private Placement32
25.06.Nurexone Biologic Inc: Nurexone unit signs MOU re exosome product distribution34
24.06.NurExone Biologic Inc: Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico527TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,7